AI Verdict
JNJ has stronger fundamentals based on our AI analysis.
JNJ vs REGN Fundamental Comparison
| Metric | JNJ | REGN |
|---|---|---|
| Revenue | $94.2B | $14.3B |
| Net Income | $26.8B | $4.5B |
| Net Margin | 28.5% | 31.4% |
| ROE | 32.9% | 14.4% |
| ROA | 13.5% | 11.1% |
| Current Ratio | 1.03x | 4.13x |
| Debt/Equity | 0.51x | 0.06x |
| EPS | $11.03 | $41.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
JNJ vs REGN: Frequently Asked Questions
Is JNJ or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), JNJ has stronger fundamentals. JNJ is rated BUY (86% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does JNJ compare to REGN fundamentally?
JOHNSON & JOHNSON has ROE of 32.9% vs REGENERON PHARMACEUTICALS, INC.'s 14.4%. Net margins are 28.5% vs 31.4% respectively.
Which stock pays higher dividends, JNJ or REGN?
JNJ has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in JNJ or REGN for long term?
For long-term investing, consider that JNJ has BUY rating with 86% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about JNJ vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For JNJ vs REGN, the AI consensus favors JNJ based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.